The long road to protect infants against severe RSV lower respiratory tract illness

Area of Science:

• Pediatrics
• Immunology
• Vaccinology

Background:

• Severe lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV) in infants is a significant global health issue.
• Despite extensive research over 50 years, effective preventive strategies for RSV LRTI have been limited, with several vaccine and antibody approaches failing due to safety or efficacy concerns.

Purpose of the Study:

• To review the historical development of respiratory syncytial virus (RSV) vaccines.
• To discuss past and current RSV vaccine strategies, including challenges and recent advancements.
• To highlight the implications of RSV disease burden and the potential impact of successful prevention.

Main Methods:

• Literature review of historical and ongoing RSV vaccine and antibody development.
• Analysis of clinical trial outcomes for various preventive strategies.
• Examination of RSV disease burden data.

Main Results:

• Previous RSV vaccine candidates, including inactivated vaccines and early F protein approaches, have failed or caused adverse events.
• Monoclonal antibodies like palivizumab and motavizumab have shown some efficacy, but with limitations.
• Recent maternal immunization trials (e.g., Novavax ResVax) and extended half-life mAbs demonstrate potential for preventing severe RSV LRTI.

Conclusions:

• Successful prevention of severe RSV LRTI is achievable through monoclonal antibodies and maternal immunization.
• Effective RSV prevention may also reduce subsequent risks of recurrent wheezing and pneumonia.
• Continued research and development are crucial for addressing the ongoing challenge of RSV disease prevention.